Effects of Rimonabant on Metabolic Risk Factors in Overweight Patients with Dyslipidemia

Cited by (999)

Items 501–600 of 999

1. Cannabinoid receptor 1 signaling in hepatocytes and stellate cells does not contribute to NAFLD
   Simeng Wang, Qingzhang Zhu, Guosheng Liang, Tania Franks, Magalie Boucher, Kendra K. Bence, Mingjian Lu, Carlos M. Castorena, Shangang Zhao, Joel Keith Elmquist et al. · 2021 · Journal of Clinical Investigation
2. Appetite and obesity: a gastroenterologist's perspective
   Michael Camilleri, April Grudell · 2007 · Neurogastroenterology & Motility
3. Elevated cannabinoid receptor 1 and G protein‐coupled receptor 55 expression in proximal tubule cells and whole kidney exposed to diabetic conditions
   Kayte A. Jenkin, Andrew J. McAinch, Yuan Zhang, Darren J. Kelly, Deanne Helena Hryciw · 2014 · Clinical and Experimental Pharmacology and Physiology
4. Melanocortin - 4 Receptor Agonists for the Treatment of Obesity
   Matthew J. Fisher, Liang Zeng Yan, John P. Mayer, Paul J. Emmerson · 2007 · Current Topics in Medicinal Chemistry
5. Contribution of CB1 blockade to the management of high-risk abdominal obesity
   Jean‐Pierre Després, Isabelle Lemieux, Natalie Alméras · 2006 · International Journal of Obesity
6. Electroacupuncture Attenuates Cerebral Ischemia-Reperfusion Injury in Diabetic Mice Through Adiponectin Receptor 1-Mediated Phosphorylation of GSK-3β
   Fan Guo, Tao Jiang, Wenying Song, Haidong Wei, Feng Wang, Lixin Liu, Lei Ma, Hong Yin, Qiang Wang, Lize Xiong · 2014 · Molecular Neurobiology
7. Investigation on the relationship between cannabinoid CB1and opioid receptors in gastrointestinal motility in mice
   Mauro A.M. Carai, Giancarlo Colombo, Gian Luigi Gessa, Ratnakumar Yalamanchili, Balapal S. Basavarajappa, Basalingappa L. Hungund · 2006 · British Journal of Pharmacology
8. Multidisciplinary Pharmacotherapeutic Options for Nonalcoholic Fatty Liver Disease
   Kei Nakajima · 2012 · International Journal of Hepatology
9. 2007 Guidelines for the Management of Arterial Hypertension The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European
   Giuseppe Mancia, Anna F. Dominiczak, Robert H. Fagard, Anthony Michael Heagerty, Sverre Erik Kjeldsen, Stéphane Laurent, Roland Erich Schmieder, Alec S. Vahanian, A. John Camm, Verónica Dean et al. · 2007
10. Cannabis: From a Plant That Modulates Feeding Behaviors toward Developing Selective Inhibitors of the Peripheral Endocannabinoid System for the Treatment of Obesity and Metabolic Syndrome
    Shira Hirsch, Joseph Tam · 2019 · Toxins
11. The role of the pancreatic endocannabinoid system in glucose metabolism
    Francisco Javier Bermúdez‐Silva, Juan Suárez, Ángel Nadal, Fernando Rodrı́guez de Fonseca · 2009 · Best Practice & Research Clinical Endocrinology & Metabolism
12. Controlled downregulation of the cannabinoid CB1 receptor provides a promising approach for the treatment of obesity and obesity-derived type 2 diabetes
    Dai Lu, Rachel Dopart, Debra A. Kendall · 2015 · Cell Stress and Chaperones
13. Caloric restriction lowers endocannabinoid tonus and improves cardiac function in type 2 diabetes
    Huub J. van Eyk, Linda D. van Schinkel, Vasudev Kantae, Charlotte E. A. Dronkers, Jos J.M. Westenberg, A. Roos, Hildo J. Lamb, J. Wouter Jukema, Amy C. Harms, Thomas Hankemeier et al. · 2018 · Nutrition and Diabetes
14. Peripheral cannabinoid 1 receptor blockade mitigates adipose tissue inflammation via NLRP3 inflammasome in mouse models of obesity
    Ji Hye Han, Hanho Shin, Jun Gi Rho, Jung‐Eun Kim, Dong H. Son, Juhwan Yoon, Yong Jun Lee, Jung‐Hyuck Park, Byung Joon Song, Chang‐Sik Choi et al. · 2018 · Diabetes Obesity and Metabolism
15. Pharmacological selection of cannabinoid receptor effectors: Signalling, allosteric modulation and bias
    Jamie J. Manning, Hayley M. Green, Michelle Glass, David B. Finlay · 2021 · Neuropharmacology
16. Treatment strategies for obesity
    John P.H. Wilding · 2007 · Obesity Reviews
17. The cannabinoid receptor 1 and its role in influencing peripheral metabolism
    Lannie O’Keefe, Anna C Simcocks, Deanne Helena Hryciw, Michael L. Mathai, Andrew J. McAinch · 2013 · Diabetes Obesity and Metabolism
18. Rimonabant: A cannabinoid receptor blocker for the treatment of metabolic and cardiovascular risk factors
    Serena Tonstad · 2006 · Nutrition Metabolism and Cardiovascular Diseases
19. Adipokines--targeting a root cause of cardiometabolic risk
    Ameet Bakhai · 2008 · QJM
20. Nonalcoholic Fatty Liver Disease: A Clinical Approach and Review
    Maitreyi Raman, Johane P. Allard · 2006 · Canadian Journal of Gastroenterology
21. Obesity
    Kerri Palamara, Harriette Rosen Mogul, Stephen J. Peterson, William H. Frishman · 2006 · Cardiology in Review
22. Blocking the Cannabinoid Receptors: Drug Candidates and Therapeutic Promises
    Giulio G. Muccioli · 2007 · Chemistry & Biodiversity
23. Novel pyrazole derivatives as neutral CB 1 antagonists with significant activity towards food intake
    Ilaria Manca, Andrea Mastinu, Francesca Olimpieri, Matteo Falzoi, Monica Sani, Stefania Ruiu, Giovanni Loriga, Alessandro Volonterio, Simone Tambaro, Mirko Emilio Heiner Bottazzi et al. · 2013 · European Journal of Medicinal Chemistry
24. Endocannabinoid system in cardiovascular disorders - new pharmacotherapeutic opportunities
    Flávio Reis, Pedro Cunha, AnaM Romão, Filipa Mascarenhas‐Melo, Helena M. Teixeira · 2011 · Journal of Pharmacy And Bioallied Sciences
25. Pursuing paradoxical proconvulsant prophylaxis for epileptogenesis
    Caren Armstrong, Robert J. Morgan, Iván Soltész · 2009 · Epilepsia
26. The Endocannabinoid System as a Target for the Treatment of Visceral Obesity and Metabolic Syndrome
    Ioannis Kyrou, George Valsamakis, Constantine Tsigos · 2006 · Annals of the New York Academy of Sciences
27. Cannabinoid CB 1 Receptor Antagonists for Atherosclerosis and Cardiometabolic Disorders
    Pál Pacher · 2008 · Arteriosclerosis Thrombosis and Vascular Biology
28. Psychosocial and pharmacological interventions for the treatment of cannabis use disorder
    Sabioni, Pamela, Le Foll, Bernard · 2018 · F1000Research
29. Opposing local effects of endocannabinoids on the activity of noradrenergic neurons and release of noradrenaline: relevance for their role in depression and in the actions of CB1 receptor antagonists
    Eszter Kirilly, László Hunyady, György Bagdy · 2012 · Journal of Neural Transmission
30. Metabolic Syndrome Affects Midterm Outcome After Coronary Artery Bypass Grafting
    Emiliano Angeloni, Giovanni Melina, Umberto Benedetto, Simone Refice, Fabio Capuano, Antonino Roscitano, Cosimo Comito, Riccardo Sinatra · 2011 · The Annals of Thoracic Surgery
31. Weight loss induced by rimonabant is associated with an altered leptin expression and hypothalamic leptin signaling in diet-induced obese mice
    Paolo Lazzari, Angela Sanna, Andrea Mastinu, Simona Cabasino, Ilaria Manca, Luca Pani · 2010 · Behavioural Brain Research
32. Cost effectiveness of duloxetine in the treatment of diabetic peripheral neuropathic pain in the UK
    Stephen M. Beard, Louise McCrink, Trong Kim Le, Ana Garcia-Cebrian, Brigitta U. Monz, Rayaz Ahmed Malik · 2007 · Current Medical Research and Opinion
33. Effect of weight‐reducing agents on glycaemic parameters and progression to Type 2 diabetes: a review
    Célia Lloret‐Linares, Jerry Richard Greenfield, Sébastien Czernichow · 2008 · Diabetic Medicine
34. The Endocannabinoid System: Mechanisms Behind Metabolic Homeostasis and Imbalance
    Stephen C. Woods · 2007 · The American Journal of Medicine
35. Antidepressant-induced undesirable weight gain: Prevention with rimonabant without interference with behavioral effectiveness
    Nikolai Gobshtis, Shimon Ben‐Shabat, Ester Fride · 2006 · European Journal of Pharmacology
36. The relationship between cannabis and cardiovascular disease: clearing the haze
    Mark Chandy, Nerea Jiménez-Téllez, Joseph C. Wu · 2025 · Nature Reviews Cardiology
37. Therapeutic regulation of apoB100 metabolism in insulin resistance in vivo
    Gerald Francis Watts, Esther M. M. Ooi, Dick C. Chan · 2009 · Pharmacology & Therapeutics
38. CB1 cannabinoid receptor antagonism: A new strategy for the treatment of liver fibrosis
    Hermann E. Wasmuth, Christian Trautwein · 2007 · Hepatology
39. CB1 Cannabinoid Receptor Inhibition: Promising Approach for Heart Failure?
    Partha Mukhopadhyay, Mohanraj Rajesh, Sándor Bátkai, Pál Pacher · 2008 · Congestive Heart Failure
40. Is Weight Loss Beneficial for Reduction of Morbidity and Mortality?
    Peter M. Nilsson · 2008 · Diabetes Care
41. Role of Gut-Related Peptides and Other Hormones in the Amelioration of Type 2 Diabetes after Roux-en-Y Gastric Bypass Surgery
    Mirella P. Hage, Bassem Y. Safadi, Ibrahim Salti, Mona Nasrallah · 2012 · ISRN Endocrinology
42. CB1 blockade-induced weight loss over 48 weeks decreases liver fat in proportion to weight loss in humans
    Robert Bergholm, Ksenia Sevastianova, A Santos, Anna Kotronen, M Urjansson, Antti Hakkarainen, Jesper Lundbom, Mirja Tiikkainen, A Rissanen, Nina M I Lundbom et al. · 2012 · International Journal of Obesity
43. The Effect of Weight Loss in Obesity and Chronic Kidney Disease
    Enrique Morales, Manuel Praga · 2012 · Current Hypertension Reports
44. Acute and chronic systemic CB1cannabinoid receptor blockade improves blood pressure regulation and metabolic profile in hypertensive (mRen2)27 rats
    Christopher L. Schaich, Hossam A. Shaltout, K. Bridget Brosnihan, A­llyn C. Howlett, Debra I. Diz · 2014 · Physiological Reports
45. The burden of type 2 diabetes: strategies to prevent or delay onset.
    Nayyar Iqbal · 2007 · PubMed Central
46. The Hope and Fear of Rimonabant
    John S. Rumsfeld · 2008 · JAMA
47. The role of triglycerides in cardiovascular risk
    Puneet Gandotra, Michael J. Miller · 2008 · Current Cardiology Reports
48. NESS06SM reduces body weight with an improved profile relative to SR141716A
    Andrea Mastinu, Marilena Pira, Gerard Aime Pinna, Carla Pisu, Maria Antonietta Casu, Roberta Reali, S. Marcello, Gabriele Murineddu, Paolo Lazzari · 2013 · Pharmacological Research
49. Cannabinoid receptor 1 mediates glucocorticoid‐induced bone loss in rats by perturbing bone mineral acquisition and marrow adipogenesis
    Jih‐Yang Ko, Re‐Wen Wu, Shu‐Jui Kuo, Ming‐Wen Chen, Da‐Wei Yeh, Huei-Ching Ke, Shin‐Long Wu, Feng‐Sheng Wang · 2011 · Arthritis & Rheumatism
50. Circuits Controlling Energy Balance and Mood: Inherently Intertwined or Just Complicated Intersections?
    Chen Liu, Syann Lee, Joel Keith Elmquist · 2014 · Cell Metabolism
51. Obesity an overview: Genetic conditions and recent developments in therapeutic interventions
    Vikram Rao, Mayuren Candasamy, Subrat Kumar Bhattamisra · 2019 · Diabetes & Metabolic Syndrome Clinical Research & Reviews
52. Cannabinoids, eating behaviour, and energy homeostasis
    Silvana‐Yanina Romero‐Zerbo, Francisco Javier Bermúdez‐Silva · 2013 · Drug Testing and Analysis
53. Omega-3 fatty acids in ileal effluent after consuming different foods containing microencapsulated fish oil powder – an ileostomy study
    Luz Sanguansri, Zhiping Shen, Rangika Weerakkody, Mary B. Barnes, Trevor J. Lockett, Mary Ann Augustin · 2012 · Food & Function
54. Clinical Use of the Metabolic Syndrome: Why the Confusion?
    Michael Joseph Blaha, Tom A. Elasy · 2006 · Clinical Diabetes
55. The CB1 receptor mediates the peripheral effects of ghrelin on AMPK activity but not on growth hormone release
    Blerina Kola, Gábor Wittmann, Ibolya Bodnár, Faisal Amin, Chung Thong Lim, Márk Oláh, Mirjam Christ‐Crain, Francesca Lolli, Hinke van Thuijl, Chrysanthia A. Leontiou et al. · 2013 · The FASEB Journal
56. The dysregulation of the endocannabinoid system in diabesity—a tricky problem
    Thomas Scherer, Christoph Buettner · 2009 · Journal of Molecular Medicine
57. Variants in the CNR1 and the FAAH Genes and Adiposity Traits in the Community
    Wolfgang Lieb, Alisa Knodle Manning, José C. Florez, Josée Dupuis, L. Adrienne Cupples, Jarred B. McAteer, Ramachandran Srini Vasan, Udo Hoffmann, Christopher J. O’Donnell, James B. Meigs et al. · 2009 · Obesity
58. A comparison between rimonabant and metformin in reducing biochemical hyperandrogenaemia and insulin resistance in patients with polycystic ovary syndrome (PCOS): a randomized open‐label parallel study
    Thozhukat Sathyapalan, Li Wei Cho, Eric S. Kilpatrick, Anne‐Marie Coady, Stephen Lawrence Atkin · 2008 · Clinical Endocrinology
59. Long-term effects of weight-reducing drugs in hypertensive patients
    Andrea Siebenhofer, Karl Horvath, Klaus Jeitler, Andrea Berghold, Anne Kathrin Stich, Eva Matyas, Nicole Pignitter, Ulrich Siering · 2009 · Cochrane Database of Systematic Reviews
60. A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents
    Mayank Kumar Sharma, Prashant Revan Murumkar, Mahesh A. Barmade, Rajani Giridhar, Mange Ram Yadav · 2015 · Expert Opinion on Therapeutic Patents
61. Pathophysiology guided treatment of nonalcoholic steatohepatitis
    Tuyet A. T. Nguyen, Arun Jayant Sanyal · 2012 · Journal of Gastroenterology and Hepatology
62. Rimonabant prevents additional accumulation of visceral and subcutaneous fat during high-fat feeding in dogs
    Joyce M. Richey, Orison O. Woolcott, Darko Stefanovski, L. Nicole Harrison, Dan Zheng, Maya Lottati, Isabel R. Hsu, Stella P. Kim, Morvarid Kabir, Karyn J. Catalano et al. · 2009 · American Journal of Physiology-Endocrinology and Metabolism
63. South Asian Ethnicity and Cardiovascular Risk
    Emad Ahmed, Ayman Ahmed El-Menyar · 2014 · Angiology
64. Effect of glucagon-like peptide-1 analogue; Exendin-4, on cognitive functions in type 2 diabetes mellitus; possible modulation of brain derived neurotrophic factor and brain Visfatin
    Omaima Mohammed Abdelwahed, Ola M. Tork, Maha Gamal el Din, Laila Ahmed Rashed, Maha Baligh Zickri · 2018 · Brain Research Bulletin
65. Cannabinoid Receptors in Metabolic Regulation and Diabetes
    Elisabeth Rohbeck, Jürgen Eckel, Tania Romacho · 2021 · Physiology
66. Appetite and Metabolic Effects of Ghrelin and Cannabinoids: Involvement of AMP-Activated Protein Kinase
    Hinke van Thuijl, Blerina Kola, Márta Korbonits · 2007 · Vitamins and hormones
67. Rimonabant induces partial seizures in a patient with a history of generalized epilepsy
    Hilde M. H. Braakman, Robert J. van Oostenbrugge, Vivianne H.J.M. van Kranen-Mastenbroek, Marc C. T. F. M. de Krom · 2009 · Epilepsia
68. Diarylimidazolyl oxadiazole and thiadiazole derivatives as cannabinoid CB1 receptor antagonists
    Jong Yup Kim, Hee Jeong Seo, Sung-Han Lee, Myung Eun Jung, Kwangwoo Ahn, Jeong‐Min Kim, Jinhwa Lee · 2008 · Bioorganic & Medicinal Chemistry Letters
69. Cannabinoid 1 Receptor Blockade Reduces Atherosclerosis with Enhances Reverse Cholesterol Transport
    Koichi Sugamura, Seigo Sugiyama, Yukio Fujiwara, Junichi Matsubara, Eiichi Akiyama, Hirofumi Maeda, Keisuke Ohba, Yasushi Matsuzawa, Masaaki Konishi, Toshimitsu Nozaki et al. · 2010 · Journal of Atherosclerosis and Thrombosis
70. Furo[2,3-b]pyridine-based cannabinoid-1 receptor inverse agonists: Synthesis and biological evaluation. Part 1
    John S. Debenham, Christina B. Madsen-Duggan, Richard B. Toupence, Thomas F. Walsh, Junying Wang, Xinchun Tong, Sanjeev Kumar, Julie Z. Lao, Tung Ming Fong, Jing Chen Xiao et al. · 2010 · Bioorganic & Medicinal Chemistry Letters
71. The Hong Kong Medical Diary
    Tmy Mok · 2010 · The HKU Scholars Hub (University of Hong Kong)
72. Adverse Impact of Cannabis on Human Health
    Mark Chandy, Masataka Nishiga, Tzu-Tang Wei, Naomi M. Hamburg, Kari Christine Nadeau, Joseph C. Wu · 2023 · Annual Review of Medicine
73. The endocannabinoid system in appetite regulation and treatment of obesity
    Marija Kurtov, Igor Rubinić, Robert Likić · 2024 · Pharmacology Research & Perspectives
74. Acute cannabinoid receptor type 1 (CB1R) modulation influences insulin sensitivity by an effect outside the central nervous system in mice
    D. Song, Robert Bandsma, Changting Xiao, L. Xi, Weijuan Shao, Tianru Jin, Gary F. Lewis · 2011 · Diabetologia
75. Weight loss in obese men by caloric restriction and high‐dose diazoxide–mediated insulin suppression
    Gerben van Boekel, Sandra Loves, Adriaan van Sorge, Janneke Ruinemans‐Koerts, Ton Rijnders, Hans de Boer · 2008 · Diabetes Obesity and Metabolism
76. Metabolic syndrome in people with a psychotic illness: is cannabis protective?
    Anna J Waterreus, Patsy Di Prinzio, Gerald Francis Watts, David Jonathan Castle, Cherrie Ann Galletly, Vera Anne Morgan · 2016 · Psychological Medicine
77. Stimulants for the Control of Hedonic Appetite
    Alison Sally Poulton, Emily Hibbert, Bernard Linton Champion, Ralph Kay Heinrich Nanan · 2016 · Frontiers in Pharmacology
78. The endocannabinoid system: Body weight and metabolic regulation
    Stefan Engeli, Jens Jordan · 2006 · Clinical cornerstone
79. Is it time to abandon excess weight loss in reporting surgical weight loss?
    Shahzeer Karmali, Daniel W. Birch, Arya Mitra Sharma · 2009 · Surgery for Obesity and Related Diseases
80. Latest advances in cannabinoid receptor antagonists and inverse agonists
    Giulio G. Muccioli, Didier M. Lambert · 2006 · Expert Opinion on Therapeutic Patents
81. The hepatic cannabinoid 1 receptor as a modulator of hepatic energy state and food intake
    Martin Cooper, Simon E. Regnell · 2013 · British Journal of Clinical Pharmacology
82. The unrelenting fall of the pharmacological treatment of obesity
    Guido Di Dalmazi, Valentina Vicennati, Renato Pasquali, Uberto Pagotto · 2013 · Endocrine
83. Targeting thermogenesis and related pathways in anti-obesity drug discovery
    John C. Clapham, Jonathan R.S. Arch · 2011 · Pharmacology & Therapeutics
84. Additive effect of rimonabant and citalopram on extracellular serotonin levels monitored with in vivo microdialysis in rat brain
    Jorge Emilio Ortega, Víctor González-Lira, Igor Horrillo, Mario Herrera‐Marschitz, Luis Felipe Callado, J. Javier Meana · 2013 · European Journal of Pharmacology
85. Anti-obesity effects of the combined administration of CB1 receptor antagonist rimonabant and melanin-concentrating hormone antagonist SNAP-94847 in diet-induced obese mice
    Aaron N.A. Verty, Sarah Haas Lockie, Aneta Stefanidis, Brian J. Oldfield · 2012 · International Journal of Obesity
86. Update on therapeutic strategies to increase adiponectin function and secretion in metabolic syndrome
    Fabrizio Montecucco, François Mach · 2009 · Diabetes Obesity and Metabolism
87. Current pharmacotherapeutic concepts for the treatment of obesity in adults
    Evgeny A. Idelevich, Wilhelm Kirch, Christoph Schindler · 2008 · Therapeutic Advances in Cardiovascular Disease
88. Naloxone and rimonabant reduce the reinforcing properties of exercise in rats.
    Erin B. Rasmussen, Conrad N. Hillman · 2011 · Experimental and Clinical Psychopharmacology
89. Sibutramine: current status as an anti-obesity drug and its future perspectives
    Bikash Sharma, David C. Henderson · 2008 · Expert Opinion on Pharmacotherapy
90. Cannabinoid receptors in atherosclerosis
    Sabine Steffens, François Mach · 2006 · Current Opinion in Lipidology
91. Beneficial effect of a chronic treatment with rimonabant on pancreatic function and β-cell morphology in Zucker Fatty rats
    Valérie Duvivier, Laure Delafoy-Plasse, Véronique Delion, Patricia Lechevalier, Jean-Christophe Le Bail, Etienne Guillot, Marie‐Pierre Pruniaux, Anne‐Marie Galzin · 2009 · European Journal of Pharmacology
92. Nicotinic acid and other therapies for raising high-density lipoprotein
    Lars A. Carlson · 2006 · Current Opinion in Cardiology
93. Is rimonabant efficacious and safe in the treatment of obesity?
    Sheila Anne Doggrell · 2008 · Expert Opinion on Pharmacotherapy
94. Cardiotoxic effects of common and emerging drugs: role of cannabinoid receptors
    Yiming Bo, Xin Zhao, Liliang Li · 2024 · Clinical Science
95. Metabolic Syndrome and Prediabetes
    Ambika R. Babu, Leon A. Fogelfeld · 2006 · Disease-a-Month
96. Remission of metabolic syndrome following a 15-week low-calorie lifestyle change program for weight loss
    Jennifer D. Lundgren, R Malcolm, Martin Binks, Patrick Mahlen O'Neil · 2008 · International Journal of Obesity
97. Endocannabinoid system overactivity and the metabolic syndrome: Prospects for treatment
    Jennifer M. Perkins, Stephen N. Davis · 2008 · Current Diabetes Reports
98. Risk of Depressive Episodes with Rimonabant
    Yvonne Buggy, Victoria R. Cornelius, Lynda Wilton, Saad Shakir · 2011 · Drug Safety
99. Endocannabinoids, Blood Pressure and the Human Heart
    Riccardo Sarzani · 2008 · Journal of Neuroendocrinology
100. Investigational therapies in the treatment of obesity
     Márcio C. Mancini, Alfredo Halpern · 2006 · Expert Opinion on Investigational Drugs